Click here to read PCMA’s letter to the Administration’s COVID-19 Task Force.
As the Pharmaceutical Care Management Association (PCMA) closely monitors the COVID-19 outbreak, our industry’s priority is that Americans have ready access to the medications that they need in the coming weeks and months. PCMA is consulting with the Department of Health and Human Services (HHS), insurers and stakeholders in the prescription drug supply chain to explore how to limit patient disruption as much as possible. Considerations include making sure that patients feel confident that they will be able to obtain an adequate supply of their medications and that, should their medication be in short supply due to the coronavirus, their pharmacy benefit manager will work with them, their pharmacy and health plan to identify a covered therapeutically equivalent alternative.
PCMA companies are following Centers for Disease Control (CDC) and other government agency recommendations and encourage everyone to visit the CDC website for the latest details, along with prevention strategies, COVID-19 symptoms, and general FAQs, at https://www.cdc.gov/coronavirus/2019-ncov/about/index.html